{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Getta BM"],"funding":["NCI NIH HHS"],"pagination":["1064-1071"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9810388"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(7)"],"pubmed_abstract":["Minimal residual disease (MRD) in acute myeloid leukemia (AML) is typically measured using multiparameter flow cytometry (MFC). Detection of leukemia mutations using multigene next-generation sequencing (NGS) can potentially be used to measure residual disease. We used a targeted 28-gene NGS panel to detect mutations and different-from-normal 10-color MFC to measure MRD in AML patients before allogeneic hematopoietic stem cell transplantation (HCT). Residual disease was defined when any abnormal blast population was detected using MFC and when any leukemia allele was detected with a variant allele frequency (VAF)  ≥ 5% using NGS. We tracked the clearance of leukemia alleles between AML diagnosis and immediately before HCT and found that mutations in DNMT3A, TET2, and JAK2 were less likely "],"journal":["Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation"],"pubmed_title":["Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation."],"pmcid":["PMC9810388"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Getta BM","Zehir A","Roshal M","Mohanty AS","Arcila ME","Devlin SM","Levine RL","Tallman MS","Giralt SA"],"additional_accession":[]},"is_claimable":false,"name":"Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.","description":"Minimal residual disease (MRD) in acute myeloid leukemia (AML) is typically measured using multiparameter flow cytometry (MFC). Detection of leukemia mutations using multigene next-generation sequencing (NGS) can potentially be used to measure residual disease. We used a targeted 28-gene NGS panel to detect mutations and different-from-normal 10-color MFC to measure MRD in AML patients before allogeneic hematopoietic stem cell transplantation (HCT). Residual disease was defined when any abnormal blast population was detected using MFC and when any leukemia allele was detected with a variant allele frequency (VAF)  ≥ 5% using NGS. We tracked the clearance of leukemia alleles between AML diagnosis and immediately before HCT and found that mutations in DNMT3A, TET2, and JAK2 were less likely ","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jul","modification":"2026-03-16T08:08:23.978Z","creation":"2024-11-14T07:57:06.553Z"},"accession":"S-EPMC9810388","cross_references":{"pubmed":["28315400"],"doi":["10.1016/j.bbmt.2017.03.017"]}}